

Andrew Haydon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4612932/andrew-haydon-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

4,306
citations

24
h-index

65
g-index

70
ext. papers

5,918
ext. citations

9.2
avg. IF

4.83
L-index

#	Paper	IF	Citations
65	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
64	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
63	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016 , 8, 346ra92	17.5	688
62	Investigation of the safety of irreversible electroporation in humans. <i>Journal of Vascular and Interventional Radiology</i> , 2011 , 22, 611-21	2.4	352
61	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
60	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019 , 68, 663-671	19.2	138
59	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
58	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 510-520	21.7	123
57	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2177-2184	2.2	107
56	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105
55	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , 2018 , 19, 562-578	21.7	93
54	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017 , 116, 1558-1563	8.7	72
53	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <i>International Journal of Cancer</i> , 2018 , 142, 238-250	7.5	53
52	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017 , 117, 921-924	8.7	52
51	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
50	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2258-64	2.2	41
49	A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 1014-23	5.7	39

48	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017 , 117, 1026-1035	8.7	33
47	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 836-847	21.7	33
46	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017 , 30, 13-27	4.5	30
45	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2140-2150	2.2	28
44	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021 , 7, 744-748	13.4	25
43	Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 507-18	7.4	24
42	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma 2020 , 8,		24
41	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 701-710	21.7	23
40	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 358-365	4.5	21
39	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12 Suppl 7, 5-12	1.9	19
38	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	4.0	18
37	Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion. <i>Diseases of the Colon and Rectum</i> , 2016 , 59, 361-8	3.1	17
36	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003620	11.6	16
35	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016 , 16, 339	4.8	11
34	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
33	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9591-9591	2.2	8
32	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 90-94	2.7	7
31	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9590-9590	2.2	7

30	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019 , 9, e031434	3	7
29	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. <i>British Journal of Cancer</i> , 2018 , 118, 1289-1295	8.7	7
28	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019 , 6, MMT28	2.1	6
27	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 150-156	4	4
26	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. <i>International Journal of Surgery</i> , 2018 , 51, 71-75	7.5	4
25	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy 2021 , 9,		4
24	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020 , 50, 1282-1285	1.6	4
23	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders 2021 , 9,		4
22	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. <i>Clinical Lung Cancer</i> , 2021 , 22, e425-e430	4.9	4
21	The acceleration of ageing in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 343-351	3.6	4
20	The Victorian Melanoma Service: A 20-year review of an Australian multidisciplinary cancer service. <i>Australasian Journal of Dermatology</i> , 2016 , 57, 235-7	1.3	3
19	Factors Explaining Socio-Economic Inequalities in Survival from Colon Cancer: A Causal Mediation Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1807-1815	4	3
18	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021 , 151, 72-83	7.5	2
17	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021 , 91 Suppl 2, 3-13	1	2
16	Reply to E. Hindle and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1
15	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020 , 61, 203-209	1.3	1
14	Concordance of somatic mutational profile in multiple primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 592-603	4.5	1
13	383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695 2021 , 9, A417-A417		1

12	Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study. <i>International Journal of Cancer</i> , 2021 , 149, 827	7.5	1
11	Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial.. <i>Cancer Prevention Research</i> , 2022 , OF1-OF11	3.2	1
10	PatientsSPreferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa107	4.6	0
9	547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab □ RP1 in patients with advanced cutaneous squamous cell carcinoma 2021 , 9, A577-A577		0
8	Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. <i>Oncologist</i> , 2021 , 26, 461-464	5.7	0
7	Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies. <i>International Journal of Cancer</i> , 2021 , 148, 2759-2773	7.5	0
6	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - AuthorsSreply. <i>Lancet Oncology, The</i> , 2021 , 22, e343-e344	21.7	0
5	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 181-183	1.9	
4	341 A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC) 2021 , 9, A367-A367		
3	340 A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC) 2021 , 9, A366-A366		
2	Reply to E. Hindi□ <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
1	Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial.. <i>Cancer Epidemiology</i> , 2022 , 79, 102173	2.8	